Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy

Tumor-intrinsic biomarkers guiding prognostic assessment of large B-cell lymphoma (LBCL) treated with CD19-chimeric antigen receptor T-cell (CAR-T) therapy remain ill-defined. This observational study examined the prognostic role of TP53 alterations, identified by DNA sequencing, in LBCL treated with CD19-CAR-T. TP53 genomic status in LBCL identifies patients potentially at increased risk for CD19-CAR-T therapy failure and, if these results are validated, should inform the design of future clinical trials.